[go: up one dir, main page]

MX2012008362A - Metodos y usos relacionados con la identificacion de un compuesto implicado en el dolor, asi como metodos de diagnostico de algesia. - Google Patents

Metodos y usos relacionados con la identificacion de un compuesto implicado en el dolor, asi como metodos de diagnostico de algesia.

Info

Publication number
MX2012008362A
MX2012008362A MX2012008362A MX2012008362A MX2012008362A MX 2012008362 A MX2012008362 A MX 2012008362A MX 2012008362 A MX2012008362 A MX 2012008362A MX 2012008362 A MX2012008362 A MX 2012008362A MX 2012008362 A MX2012008362 A MX 2012008362A
Authority
MX
Mexico
Prior art keywords
methods
pain
well
compound involved
identification
Prior art date
Application number
MX2012008362A
Other languages
English (en)
Inventor
Martin Michaelis
Mathias Gebauer
Danping Ding-Pfennigdorff
Anke M Schulte
Christiane Metz-Weidmann
Daniel Ziemek
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2012008362A publication Critical patent/MX2012008362A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un método de identificación de un compuesto implicado en el dolor, al uso del ácido nucleico de ll2rg o la proteína ll2rg para identificar un compuesto implicado en el dolor, así como a métodos de diagnóstico de algesia que implican al mismo.
MX2012008362A 2010-01-21 2011-01-20 Metodos y usos relacionados con la identificacion de un compuesto implicado en el dolor, asi como metodos de diagnostico de algesia. MX2012008362A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305068A EP2348129A1 (en) 2010-01-21 2010-01-21 Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
PCT/EP2011/050776 WO2011089192A1 (en) 2010-01-21 2011-01-20 Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia

Publications (1)

Publication Number Publication Date
MX2012008362A true MX2012008362A (es) 2012-08-08

Family

ID=42115310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008362A MX2012008362A (es) 2010-01-21 2011-01-20 Metodos y usos relacionados con la identificacion de un compuesto implicado en el dolor, asi como metodos de diagnostico de algesia.

Country Status (13)

Country Link
US (1) US20130059745A1 (es)
EP (2) EP2348129A1 (es)
JP (1) JP2013517759A (es)
KR (1) KR20120128634A (es)
CN (1) CN102803514A (es)
AU (1) AU2011208728A1 (es)
BR (1) BR112012017938A2 (es)
CA (1) CA2786961A1 (es)
IL (1) IL220827A0 (es)
MX (1) MX2012008362A (es)
RU (1) RU2012135297A (es)
SG (1) SG182650A1 (es)
WO (1) WO2011089192A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI963989L (fi) 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
GB2377940A (en) * 2001-07-27 2003-01-29 Warner Lambert Co Identification and use of molecules implicated in pain
US20030216341A1 (en) * 2002-02-14 2003-11-20 Hermann Lubbert Multiple genes relevant for the characterization, diagnosis, and manipulation of neuropathic pain
EP1336661A1 (en) * 2002-02-14 2003-08-20 Biofrontera Pharmaceuticals AG Multiple genes relevant for the characterisation, diagnosis, and manipulation of neuropatic pain
US20050250090A1 (en) * 2003-10-28 2005-11-10 Edward Kaftan Assay systems and methods for detecting molecules that interact with SK2 channels
WO2006091254A1 (en) * 2005-02-18 2006-08-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Identification of molecular diagnostic markers for endometriosis in blood lymphocytes
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof

Also Published As

Publication number Publication date
EP2348129A1 (en) 2011-07-27
RU2012135297A (ru) 2014-02-27
IL220827A0 (en) 2012-08-30
BR112012017938A2 (pt) 2017-06-27
AU2011208728A1 (en) 2012-08-09
US20130059745A1 (en) 2013-03-07
EP2526204A1 (en) 2012-11-28
CA2786961A1 (en) 2011-07-28
KR20120128634A (ko) 2012-11-27
SG182650A1 (en) 2012-08-30
JP2013517759A (ja) 2013-05-20
CN102803514A (zh) 2012-11-28
WO2011089192A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
HK1211260A1 (en) Method and kit for nucleic acid sequencing
WO2012009644A3 (en) Methods to identify synthetic and natural rna elements that enhance protein translation
WO2014145820A3 (en) Multiple tagging of long dna fragments
EA201590027A1 (ru) Способы детекции заболеваний или состояний
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EP3355057A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
GB201014805D0 (en) Microfluidics based assay device
BR112013001752A2 (pt) método de detectar doenças ou condições usando células fagocídicas
IT1391619B1 (it) Metodo per l'individuazione, selezione e analisi di cellule tumorali
PH12014501108A1 (en) Anti-il-36r antibodies
WO2014107599A3 (en) Compositions and methods for detecting protease activity in biological systems
MA34091B1 (fr) Anticorps anti-cd40
WO2012159025A3 (en) Chromosome conformation analysis
GB201219137D0 (en) Direct nucleic acid amplification kit, reagent and method
EP3486657A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
SI2658444T1 (sl) Postopek za izvedbo učinkovitega biosenzorja in ustrezni biosenzor, substrat in komplet za vstavljanje
DE112010000972A5 (de) Vorrichtung für eine Übertragung von Drehmomenten
BR112015008621A2 (pt) Métodos e kit de diagnóstico e/ou prognóstico in vitro microconjunto de ácidos nucleicos.
HK1198591A1 (en) Oxmif as a diagnostic marker
HK1213194A1 (zh) 用於新型的结合蛋白质pcsk9
WO2012137180A3 (en) Biomarkers of immunotherapy efficacy
WO2011140334A3 (en) Compounds, methods of making or identifying compounds, and uses thereof
WO2012080929A3 (fr) Utilisation de l'ide comme biomarqueur d'un etat du cuir chevelu
WO2011085134A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
MX2012008362A (es) Metodos y usos relacionados con la identificacion de un compuesto implicado en el dolor, asi como metodos de diagnostico de algesia.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal